



(51) International Patent Classification:

A61P 31/18 (2006.01) C07K 16/10 (2006.01)
C07K 14/73 (2006.01) C07K 16/28 (2006.01)

(21) International Application Number:

PCT/US2021/047165

(22) International Filing Date:

23 August 2021 (23.08.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/070,141 25 August 2020 (25.08.2020) US
63/163,713 19 March 2021 (19.03.2021) US

(71) Applicant: GILEAD SCIENCES, INC. [US/US]; 333
Lakeside Drive, Foster City, California 94404 (US).

(72) Inventors: BACA, Manuel; c/o Gilead Sciences, Inc.,
333 Lakeside Drive, Foster City, California 94404 (US).
BLAIR, Wade S.; c/o Gilead Sciences, Inc., 333 Lake-
side Drive, Foster City, California 94404 (US). CARR,
Brian A.; c/o Gilead Sciences, Inc., 333 Lakeside Drive,
Foster City, California 94404 (US). CLANCY, Sheila

B.; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster
City, California 94404 (US). GOLDSMITH, Joshua; c/
o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City,
California 94404 (US). HUNG, Magdeleine S.; c/o Gilead
Sciences, Inc., 333 Lakeside Drive, Foster City, California
94404 (US). KANWAR, Manu; c/o Gilead Sciences, Inc.,
333 Lakeside Drive, Foster City, California 94404 (US).
MOLDT, Brian; 1474 Elm Street, San Carlos, California
94070 (US). NAGEL, Mark; c/o Gilead Sciences, Inc.,
333 Lakeside Drive, Foster City, California 94404 (US).
PACE, Craig S.; 812 Standish Road, Pacifica, Califor-
nia 94044 (US). PAN, YenRu; c/o Gilead Sciences, Inc.,
333 Lakeside Drive, Foster City, California 94404 (US).
STEPHENSON, Heather T.; c/o Gilead Sciences, Inc.,
333 Lakeside Drive, Foster City, California 94404 (US).
THOMSEN, Nathan D.; c/o Gilead Sciences, Inc., 333
Lakeside Drive, Foster City, California 94404 (US).

(74) Agent: WAHLSTEN, Jennifer L. et al.; Gilead Sciences,
Inc., 333 Lakeside Drive, Foster City, California 94404
(US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,

(54) Title: MULTI-SPECIFIC ANTIGEN BINDING MOLECULES TARGETING HIV AND METHODS OF USE




Fig. 1

(57) Abstract: Provided are multi- specific antigen binding molecules, including bispecific antibodies, that bind to CD3 and an HIV antigen, including HIV envelope protein gp120. Also provided are methods of using such antigen binding molecules to treat or prevent HIV infection.

[Continued on next page]

CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

- (84) Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*